Pharmaceutical News

RSS

FDA approves Novartis' Ilaris for treatment of active systemic juvenile idiopathic arthritis

Novartis announced that the US Food and Drug Administration has approved Ilaris (canakinumab) for the treatment of active systemic juvenile idiopathic arthritis in patients aged 2 years and older.

10 May 2013

Mathematical model with prognostic factors predicts treatment effect with bevacizumab in colorectal cancer patients

Certara-, a leading provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through drug development, announced that its Pharsight Consulting Services has developed a mathematical model of tumor growth inhibition, which when combined with baseline prognostic factors, predicts treatment effect with bevacizumab for patients with metastatic colorectal cancer.

9 May 2013

European Patent Office issues notice of intent to grant patent for Nuvo Research's PENNSAID 2%

Nuvo Research Inc., a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain today announced that the European Patent Office has issued a notice of Intention to Grant a European Patent that provides protection for the Company's PENNSAID 2% product.

9 May 2013

Trevena, Forest sign collaborative agreement to develop TRV027 for treatment of ADHF

Trevena, Inc., a clinical stage pharmaceutical company and the leader in the discovery and development of G-protein coupled receptor biased ligands, and Forest Laboratories Holding Limited, a subsidiary of Forest Laboratories Inc., an international pharmaceutical company, announced today that they have entered into a collaborative licensing option agreement for the development of TRV027, an AT1R biased-ligand that recently completed Phase 2a clinical trials.

9 May 2013

Products from The Compounding Shop lack sterility assurance, FDA warns

The U.S. Food and Drug Administration is alerting health care providers, hospital supply managers, and pharmacists that the FDA's preliminary findings of practices at The Compounding Shop of St. Petersburg, Fla., raise concerns about a lack of sterility assurance for sterile drugs produced at and distributed from this site.

9 May 2013

Antitumor medication from natural origins on the rise

Natural phenolic compounds play an important role in cancer prevention and treatment. Researchers who examine the medicinal herbs and dietary plants that can aid in cancer treatment and prevention have found that antitumor medication from natural origins is on the rise.

9 May 2013

Nearly 5 million asthmatics with ABPA could benefit from antifungal treatment, say researchers

An estimated 4,837,000 asthmatics with allergic bronchopulmonary aspergillosis (ABPA) could benefit substantially from antifungal treatment, say researchers from the University of Toronto and Manchester University.

9 May 2013

FDA accepts Merck's BLA for investigational ragweed pollen sublingual allergy immunotherapy tablet

Merck, known as MSD outside the United States and Canada, today announced that the Biologics License Application for its investigational ragweed pollen (Ambrosia artemisiifolia) sublingual allergy immunotherapy tablet has been accepted for review by the U.S. Food and Drug Administration.

9 May 2013

Patients with ASPS appear to benefit from anti-cancer drug, cediranib

Patients with advanced alveolar soft part sarcoma (ASPS), a rare cancer, achieved some control of their disease using an experimental anti-cancer drug called cediranib.

8 May 2013

Researchers discover potential treatment for deadly, drug-resistant bacterial infections

Through the serendipity of science, researchers at the University of Pittsburgh have discovered a potential treatment for deadly, drug-resistant bacterial infections that uses the same approach that HIV uses to infect cells.

8 May 2013

Antidepressants can increase risk of C. difficile infection in depressed patients

Adults with depression and who receive certain types of anti-depressants have an increased risk of developing Clostridium difficile, a costly and serious hospital-associated infection, according to a new University of Michigan Health System study.

8 May 2013

New VLP vaccine candidate produced for H7N9 virus

Medicago Inc., a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today announced that it has successfully produced a new VLP vaccine candidate for the H7N9 virus that is responsible for the current influenza outbreak in China.

8 May 2013

New bill could open up new territory for MMJ innovations

As Neutra Corp. works to deliver new innovations making medical marijuana safer and more effective than ever before, the market for such breakthroughs is expanding rapidly. Just last month, two new state legislatures—Pennsylvania and Alabama—saw favorable cannabis bills formally introduced.

8 May 2013

IDIBELL signs patent licensing agreement with Minoryx

The Bellvittge Biomedical Research Institute has signed a licensing agreement with the Spanish biotechnology company Minoryx of a patent for the treatment of X-linked adrenoleukodystrophy, a rare serious neurodegenerative disease which has no effective treatment.

8 May 2013

Taking strong anticholinergic doubles risk of developing cognitive impairment in older adults

Research from the Regenstrief Institute, the Indiana University Center for Aging Research and Wishard-Eskenazi Health on medications commonly taken by older adults has found that drugs with strong anticholinergic effects cause cognitive impairment when taken continuously for as few as 60 days.

8 May 2013

St. Louis College of Pharmacy, DEA partner to safely dispose of unwanted medication

Rain did not hold back anyone in St. Louis looking to safely dispose of unwanted and expired medication. On April 27, a record 16,311 pounds of medication from the St. Louis metropolitan area was discarded as part of the St. Louis Medication Disposal Initiative.

8 May 2013

Scientists discover how Alzheimer's pharmaceuticals sharpen the brain's performance

Scientists at the Virginia Tech Carilion Research Institute have discovered how the predominant class of Alzheimer's pharmaceuticals might sharpen the brain's performance.

8 May 2013

Cubist receives Fast Track designation from FDA for late-stage antibiotic candidate

Cubist Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted the Company's late-stage antibiotic candidate ceftolozane/tazobactam (CXA-201) Fast Track status in the previously granted Qualified Infectious Disease Product indications, Hospital-Acquired Bacterial Pneumonia/Ventilator-Associated Bacterial Pneumonia and Complicated Urinary Tract Infections.

8 May 2013

New treatment could potentially benefit Irish SLE patients, find researchers

Researchers from the Royal College of Surgeons in Ireland have discovered that a new treatment for the inflammatory condition, Systemic Lupus Erythmstosus could potentially benefit Irish patients who suffer from the condition.

8 May 2013

Janssen enrolls patients in expanded access program for mantle cell lymphoma

Janssen Research & Development, LLC (Janssen) today announced patients are now enrolling in a multicenter, open-label expanded access program (EAP) in the United States for the investigational oral Bruton's Tyrosine Kinase (BTK) inhibitor ibrutinib, which is being jointly developed by Janssen and Pharmacyclics, Inc.

7 May 2013

Pharmaceutical News

FDA approves Novartis' Ilaris for treatment of active systemic juvenile idiopathic arthritis

Mathematical model with prognostic factors predicts treatment effect with bevacizumab in colorectal cancer patients

European Patent Office issues notice of intent to grant patent for Nuvo Research's PENNSAID 2%

Trevena, Forest sign collaborative agreement to develop TRV027 for treatment of ADHF

Products from The Compounding Shop lack sterility assurance, FDA warns

Antitumor medication from natural origins on the rise

Nearly 5 million asthmatics with ABPA could benefit from antifungal treatment, say researchers

FDA accepts Merck's BLA for investigational ragweed pollen sublingual allergy immunotherapy tablet

Patients with ASPS appear to benefit from anti-cancer drug, cediranib

Researchers discover potential treatment for deadly, drug-resistant bacterial infections

Antidepressants can increase risk of C. difficile infection in depressed patients

New VLP vaccine candidate produced for H7N9 virus

New bill could open up new territory for MMJ innovations

IDIBELL signs patent licensing agreement with Minoryx

Taking strong anticholinergic doubles risk of developing cognitive impairment in older adults

St. Louis College of Pharmacy, DEA partner to safely dispose of unwanted medication

Scientists discover how Alzheimer's pharmaceuticals sharpen the brain's performance

Cubist receives Fast Track designation from FDA for late-stage antibiotic candidate

New treatment could potentially benefit Irish SLE patients, find researchers

Janssen enrolls patients in expanded access program for mantle cell lymphoma

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News